JP2011502968A5 - - Google Patents

Download PDF

Info

Publication number
JP2011502968A5
JP2011502968A5 JP2010531519A JP2010531519A JP2011502968A5 JP 2011502968 A5 JP2011502968 A5 JP 2011502968A5 JP 2010531519 A JP2010531519 A JP 2010531519A JP 2010531519 A JP2010531519 A JP 2010531519A JP 2011502968 A5 JP2011502968 A5 JP 2011502968A5
Authority
JP
Japan
Prior art keywords
preparation according
preparation
luteinizing hormone
concentration
hlh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010531519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502968A (ja
JP5551601B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/064679 external-priority patent/WO2009056569A1/en
Publication of JP2011502968A publication Critical patent/JP2011502968A/ja
Publication of JP2011502968A5 publication Critical patent/JP2011502968A5/ja
Application granted granted Critical
Publication of JP5551601B2 publication Critical patent/JP5551601B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010531519A 2007-11-01 2008-10-29 Lh液体調製物 Active JP5551601B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07119832 2007-11-01
EP07119832.9 2007-11-01
US448107P 2007-11-28 2007-11-28
US61/004,481 2007-11-28
PCT/EP2008/064679 WO2009056569A1 (en) 2007-11-01 2008-10-29 Lh liquid formulations

Publications (3)

Publication Number Publication Date
JP2011502968A JP2011502968A (ja) 2011-01-27
JP2011502968A5 true JP2011502968A5 (enExample) 2011-12-22
JP5551601B2 JP5551601B2 (ja) 2014-07-16

Family

ID=39167502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010531519A Active JP5551601B2 (ja) 2007-11-01 2008-10-29 Lh液体調製物

Country Status (25)

Country Link
US (1) US8664369B2 (enExample)
EP (1) EP2219607B1 (enExample)
JP (1) JP5551601B2 (enExample)
KR (1) KR101513181B1 (enExample)
CN (1) CN101842083B (enExample)
AU (1) AU2008320844B2 (enExample)
BR (1) BRPI0818324B8 (enExample)
CA (1) CA2700662C (enExample)
CY (1) CY1113121T1 (enExample)
DK (1) DK2219607T3 (enExample)
EA (1) EA019432B1 (enExample)
EC (1) ECSP10010224A (enExample)
ES (1) ES2393233T3 (enExample)
HR (1) HRP20120660T1 (enExample)
IL (1) IL205105A (enExample)
MX (1) MX2010004639A (enExample)
MY (1) MY153976A (enExample)
NZ (1) NZ583991A (enExample)
PL (1) PL2219607T3 (enExample)
PT (1) PT2219607E (enExample)
RS (1) RS52566B (enExample)
SI (1) SI2219607T1 (enExample)
UA (1) UA101484C2 (enExample)
WO (1) WO2009056569A1 (enExample)
ZA (1) ZA201001907B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc eMIPを有効成分とする水溶性製剤
EP3202394A1 (de) * 2009-07-06 2017-08-09 Sanofi-Aventis Deutschland GmbH Wässrige insulinzubereitungen enthaltend methionin
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
PT2554183T (pt) 2009-11-13 2018-07-09 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2015006997A (es) * 2012-12-26 2015-09-23 Wockhardt Ltd Composicion farmaceutica.
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN105899191B (zh) 2014-01-09 2020-06-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
KR20160104724A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
RU2016132340A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулина аспарта
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5681302A (en) * 1994-06-14 1997-10-28 Minnesota Mining And Manufacturing Company Elastic sheet-like composite
AU707796B2 (en) * 1995-03-21 1999-07-22 Merck Serono Sa HCG liquid formulations
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
KR20010083126A (ko) * 1998-07-23 2001-08-31 피터 지. 스트링거 여포자극 호르몬 및 여포자극 호르몬 변이체 제형, 제품및 방법
EP1599222B1 (en) * 2003-01-08 2009-03-04 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
MXPA05010635A (es) * 2003-04-02 2005-12-12 Ares Trading Sa Formulaciones farmaceuticas liquidas de hormona estimulante de foliculos y hormona luteinizante junto con un surfactante no ionico.

Similar Documents

Publication Publication Date Title
JP2011502968A5 (enExample)
HRP20120660T1 (hr) Tekuće formulacije lh
HRP20200998T1 (hr) Postupak i sastav za liječenje okularne hipertenzije i glaukoma
FI4374878T3 (fi) Karbetosiinia käsittävä farmaseuttinen koostumus
JP2013543492A5 (enExample)
KR101940341B1 (ko) 약학 조성물
JP2015527402A5 (enExample)
NO329930B1 (no) Farmasoytisk parenteral blanding inneholdende bifosfonat, et chelaterende middel og farmasoytisk akseptabelt tilsetningsmiddel, fremgangsmate for fremstilling av slike samt anordning for frigjoring inneholdende slike
JP2012519695A5 (enExample)
US20250195439A1 (en) Method for treating local lesion disease
JP2015524444A5 (enExample)
HRP20110444T1 (hr) Formulacije paratiroidnih hormona i njihove uporabe
CN102821782B (zh) 促卵泡激素的液体配制品
TW201542239A (zh) 穩定液體調配物
JP2015535237A5 (enExample)
BRPI0920973B1 (pt) composição aquosa contendo hormônio estimulanete de folículos
JP2018532806A5 (enExample)
JP5149308B2 (ja) 局所的鼻腔投与のためのオロパタジンの製剤
HRP20140676T1 (hr) Formulacije deoksikolne kiseline i njezinih soli
KR20220116468A (ko) 펩티드 및 다당류의 새로운 접합체
CA2797658A1 (en) Casein peptide for use in the treatment of uterine infections
HRP20211696T1 (hr) Postupak izrade fluoriranih olefina
CN100553674C (zh) 一种重组人甲状旁腺激素(1-84)药物组合物及其制备方法
RU2011134414A (ru) Комбинация фульвовой кислоты для лечения различных состояний и болезней
CN101972257B (zh) 一种含有莫西沙星的药物组合物